Exicure Inc. Sells GPC-100 Program Assets for KRW 6.5 Billion
News related to:Exicure, Inc · 1 min read
WILMINGTON, Del., Nov. 10, 2026 /CourierPR/ -- Exicure, Inc., a biotechnology company focused on developing nucleic acid therapies, announced on November 4, 2026, that it has entered into an agreement to sell the assets of its GPC-100 (burixafor) program to GPCRT Inc. for KRW 6.5 billion (approximately US$4.8 million).
The assets to be sold include the Company’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc., which was signed on January 19, 2025. This agreement covers the related contracts, intellectual property, clinical and regulatory data, materials, and equipment used in the GPC-100 program. The program is currently being evaluated for its potential to improve stem cell mobilization in patients with multiple myeloma and sickle cell disease.
GPCRT Inc., a company organized under the laws of the Republic of Korea, will pay the purchase price in installments. KRW 500 million has already been paid and will be credited against the total purchase price. An additional KRW 2.0 billion is due on or before November 16, 2026, with the remaining KRW 4.0 billion to be paid at the closing. The closing is subject to customary closing conditions, including required approvals and third-party consents, as well as a waiver and release from GPCR Therapeutics, Inc.
Following the closing, GPCRT Inc. will assume the obligations under the License and Collaboration Agreement, including future milestone and royalty payments. GPCRT Inc. will also bear the costs of the GPC-100 program incurred on or after September 1, 2026. Exicure, Inc. and its wholly owned subsidiary, GPCR Therapeutics USA Inc., will retain all other liabilities, including those incurred before September 1, 2026.
The sale of the GPC-100 program assets is part of Exicure, Inc.’s ongoing evaluation of strategic alternatives intended to maximize stockholder value. The Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (SEC) on March 25, 2026, provides additional information regarding the Agreement.